secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061539
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports Q3 net loss $122.2M, FDA clears NTLA-2001 Phase 3 IND for ATTR-CM
--------------------------------------------------------------------------------

- FDA cleared IND for NTLA-2001 Phase 3 MAGNITUDE trial in ATTR cardiomyopathy; on track to initiate by year-end.
- Phase 1 data: median serum TTR reduction 91% in 62 patients; durable reduction at 12+ months.
- NTLA-2002 Phase 2 enrollment on track to complete Q4 2023; received EMA PRIME designation for HAE.
- Expanded Regeneron collaboration in neurological and muscular diseases; $30M payment expected H1 2024.
- Q3 net loss $122.2M vs $113.2M YoY; cash, equivalents and marketable securities $992.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023061539/0000950170-23-061539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023061539/ntla-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer